Edward Dabrowski, MD
Physical Medicine & Rehabilitation · Roseville, MINPI 1548230253
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 57 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 47.6% of the total. Reporting peaked in 2019 at $48,300 and has fallen 55.8% since, to $21,326 in 2025. Among physical medicine & rehabilitation clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 717 payments — averaging $233.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$80K
- AbbVie$45K
- Acadia Pharmaceuticals Inc$15K
- MDD US Operations, LLC$10K
- Ipsen Innovation$5K
- PTC Therapeutics, Inc.$3K
- plus $9K from 51 others
Across 120 payments — averaging $2007.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$114K
- Ipsen Biopharmaceuticals, Inc$99K
- Merz Pharmaceuticals, LLC$16K
- Neurocrine Biosciences, Inc.$8K
- Ipsen Innovation$3K
- Merz North America, Inc.$2K
What the payments were for
- Consulting fees$39,16523%
- Speaking & faculty fees$95,61857%
- Travel & lodging$14,0088%
- Food & beverage$18,23811%
- Education$1730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$167,202 in reported general payments places this provider in the 95th percentile of 469 physical medicine & rehabilitation providers in Michigan.
See all physical medicine & rehabilitation providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyclarysOmaveloxolone | 15 | $467,196 |
| OnfiClobazam | 12 | $56,597 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $34,127 |
| Baclofen | 180 | $31,550 |
| Chlorpromazine Hcl | 24 | $14,392 |
| Glycopyrrolate | 19 | $11,093 |
| DepakoteDivalproex Sodium | 13 | $10,745 |
| Clonazepam | 245 | $8,340 |
| Dantrolene Sodium | 76 | $7,077 |
| Carbamazepine | 16 | $4,015 |
| Lacosamide | 12 | $3,756 |
| Carbamazepine ErCarbamazepine | 27 | $3,353 |
| Levetiracetam | 62 | $3,105 |
| Aripiprazole | 11 | $3,061 |
| Methylphenidate ErMethylphenidate Hcl | 23 | $2,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenSkyclarys | $576 | $467,19615 claims |
| CSL BehringHizentra | $59 | $34,12714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 469 physical medicine & rehabilitation providers in Michigan.
Other physical medicine & rehabilitation in Roseville
- Erika ErlandsonAnn Arbor$54K
- Gianna Maria RodriguezAnn Arbor$41K
- Mathew SaffarianEast Lansing$24K
- Jason PeterTroy$20K
- David WiersemaSaginaw$17K
- Satyum ParikhWarren$11K
- Reginald KapteynMuskegon$11K
- Emily GladstoneGrand Rapids$10K
- In YoonDearborn$10K
- Hayden FranzAnn Arbor$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.